| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 14, 2025 5:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 14, 2025 5:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/17/2025 | $9.00 | Buy | D. Boral Capital |
D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00
HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy
HC Wainwright & Co. initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $7.00
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety profile HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces positive data from the ReSPECT-LM Phase 1 single dose escalation trial presented at the podium at the SNO/ASCO CNS Metastases Conference in Baltimore, MD. The data dem
HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders' equity of $3 million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"), as of June 30, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5 million in stockholders' equity. As previously reported, on June 3, 2025, the Nasdaq Listing Qualifications Department (the "Staff") notified the Company that, as of March 31, 2025, the Company no lo
Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. "The second quarter of 2025 marked steady execution and progress on our key strategic initiatives: clinical development o
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
424B3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
EFFECT - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his
AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a
SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. "The second quarter of 2025 marked steady execution and progress on our key strategic initiatives: clinical development o
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC ("CNSide"). The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients s
HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, June 26, 2025 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, June 26, 2025 @ 9:00 AM ET Webcast: https://edge.media-server.com/mmc/p/97egitn8 Dial-in Link: https://register-conf.media-server.com/re